Metagenomi, Inc. Common Stock (MGX)
MGX Stock Price Chart
Explore Metagenomi, Inc. Common Stock interactive price chart. Choose custom timeframes to analyze MGX price movements and trends.
MGX Company Profile
Discover essential business fundamentals and corporate details for Metagenomi, Inc. Common Stock (MGX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
6 Apr 2006
Employees
202.00
Website
https://www.metagenomi.coCEO
Brian Charles Thomas
Description
Metagenomi, Inc., a gene editing biotechnology company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.
MGX Financial Timeline
Browse a chronological timeline of Metagenomi, Inc. Common Stock corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 12 Nov 2025
EPS estimate is -$0.60.
Earnings released on 12 Aug 2025
EPS came in at -$0.54 surpassing the estimated -$0.68 by +20.59%, while revenue for the quarter reached $8.51M , beating expectations by +7.49%.
Earnings released on 13 May 2025
EPS came in at -$0.68 falling short of the estimated -$0.62 by -9.68%, while revenue for the quarter reached $4.13M , missing expectations by -50.28%.
Earnings released on 17 Mar 2025
EPS came in at -$0.63 falling short of the estimated -$0.62 by -1.61%, while revenue for the quarter reached $9.61M , beating expectations by +4.15%.
Earnings released on 13 Nov 2024
EPS came in at -$0.45 surpassing the estimated -$0.70 by +35.71%, while revenue for the quarter reached $11.51M , beating expectations by +70.35%.
Earnings released on 14 Aug 2024
EPS came in at -$0.29 surpassing the estimated -$0.59 by +50.85%, while revenue for the quarter reached $20.01M , beating expectations by +58.17%.
Earnings released on 14 May 2024
EPS came in at -$1.19 falling short of the estimated -$0.95 by -25.26%, while revenue for the quarter reached $11.16M , beating expectations by +42.02%.
Earnings released on 10 Feb 2024
EPS came in at -$0.51 surpassing the estimated -$2.04 by +74.76%, while revenue for the quarter reached $12.40M , beating expectations by +6.89%.
Earnings released on 30 Sept 2023
EPS came in at -$0.53 , while revenue for the quarter reached $12.36M .
Earnings released on 30 Jun 2023
EPS came in at -$0.35 , while revenue for the quarter reached $11.34M .
Earnings released on 31 Mar 2023
EPS came in at -$0.54 , while revenue for the quarter reached $8.66M .
Earnings released on 31 Dec 2022
EPS came in at -$0.39 , while revenue for the quarter reached $5.60M .
Earnings released on 29 Sept 2022
EPS came in at -$0.28 , while revenue for the quarter reached $4.91M .
Earnings released on 30 Jun 2022
EPS came in at -$1.57 , while revenue for the quarter reached $3.35M .
Earnings released on 31 Mar 2022
EPS came in at -$1.57 , while revenue for the quarter reached $3.35M .
MGX Stock Performance
Access detailed MGX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.